As a result of, in accordance with previously announced information, the directed issue of 40,960,295 Class B shares to Frusipe Intressenter Holding AB and the conversion of convertibles into 1,041,561,688 Class B shares completed on 1 October 2026 as well as the conversion of convertibles into 206,220,244 Class B shares completed on 7 October 2026, the number of shares and votes in Episurf Medical AB (publ) ("Episurf") has changed.
Through the above-mentioned changes, the total number of shares in Episurf as of 30 October 2026 amounts to 16,280,578,740, of which 473,357 are Class A shares and 16,280,105,383 are Class B shares, and the total number of votes in Episurf amounts to 16,281,525,454.
For further information, please contact:
Jens Andersson, CEO, Episurf Medical
Tel: +46 (0) 768 55 67 02
Email: jens.andersson@episurf.se
Jonathan Tillander, IR, Episurf Medical
Tel: +46 (0) 760 76 80 22
Email: jonathan.tillander@episurf.se
This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 09:00 CET on 30 October 2026.
About Episurf Medical
Episurf Medical is a property company with exposure to a diversified portfolio of property assets. The Company's objective is to create value growth through the acquisition and management of Nordic properties. The Company also has a medical technology operation based on the individualized implant Episealer® and associated surgical instruments, which are used to treat cartilage injuries in joints. Episurf Medical's head office is in Stockholm, Sweden.
THIS PRESS RELEASE HAS BEEN PUBLISHED IN SWEDISH AND IN ENGLISH. IN THE EVENT OF ANY DISCREPANCIES BETWEEN THE LANGUAGE VERSIONS, THE SWEDISH VERSION SHALL PREVAIL.